These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 30700046)
1. Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21 Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rasappan P; Rathinavelu A Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30700046 [TBL] [Abstract][Full Text] [Related]
2. Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells. Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rathinavelu A Cells; 2018 Dec; 8(1):. PubMed ID: 30583560 [TBL] [Abstract][Full Text] [Related]
3. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma. Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681 [TBL] [Abstract][Full Text] [Related]
4. Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy. Chen K; Xin X; Qiu L; Li W; Guan G; Li G; Qiao M; Zhao X; Hu H; Chen D Acta Biomater; 2019 Dec; 100():118-131. PubMed ID: 31568878 [TBL] [Abstract][Full Text] [Related]
5. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models. Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271 [TBL] [Abstract][Full Text] [Related]
6. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420 [TBL] [Abstract][Full Text] [Related]
7. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer. Zanjirband M; Edmondson RJ; Lunec J Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080 [TBL] [Abstract][Full Text] [Related]
8. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027 [TBL] [Abstract][Full Text] [Related]
9. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells. Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma. Phelps D; Bondra K; Seum S; Chronowski C; Leasure J; Kurmasheva RT; Middleton S; Wang D; Mo X; Houghton PJ Pediatr Blood Cancer; 2015 Aug; 62(8):1345-52. PubMed ID: 25832557 [TBL] [Abstract][Full Text] [Related]
11. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist. Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238 [TBL] [Abstract][Full Text] [Related]
13. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21 Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736 [TBL] [Abstract][Full Text] [Related]
15. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Huang L; Pardee AB Mol Med; 2000 Oct; 6(10):849-66. PubMed ID: 11126200 [TBL] [Abstract][Full Text] [Related]
16. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines. Feng X; Han H; Zou D; Zhou J; Zhou W Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517 [TBL] [Abstract][Full Text] [Related]
17. Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer. Yu SY; Liao CH; Chien MH; Tsai TY; Lin JK; Weng MS J Agric Food Chem; 2014 Mar; 62(9):2085-95. PubMed ID: 24533688 [TBL] [Abstract][Full Text] [Related]
18. Gene delivery of cyclin-dependent kinase inhibitors p21Waf1 and p27Kip1 suppresses proliferation of MCF-7 breast cancer cells in vitro. Jiang D; Wang X; Liu X; Li F Breast Cancer; 2014 Sep; 21(5):614-23. PubMed ID: 23338153 [TBL] [Abstract][Full Text] [Related]
19. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. Ding Q; Zhang Z; Liu JJ; Jiang N; Zhang J; Ross TM; Chu XJ; Bartkovitz D; Podlaski F; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B J Med Chem; 2013 Jul; 56(14):5979-83. PubMed ID: 23808545 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells. Laurenzana A; Balliu M; Cellai C; Romanelli MN; Paoletti F PLoS One; 2013; 8(3):e58267. PubMed ID: 23469273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]